Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2022

View Archived Issues

Discovery of GB-1101, selective oral HDAC6 inhibitor with potent antitumor activity in vivo

Gannex Pharma presents new FXR agonists

Novel biomarkers for identifying progression of diabetic retinopathy

XuanZhu Pharma divulges AhR antagonists

Gasherbrum Bio identifies new GLP-1 receptor agonists

New PADI4 inhibitors disclosed by Helios-Huaming BioPharma

Jiangsu Simcere Pharmaceutical synthesizes new Mat2A inhibitors

Celgene ERK/NLK inhibitor CC-91516 shows activity against BRAF and CTNNB1 mutant tumors

Targeting NR2E3 is a potential approach to avoid photoreceptor degeneration in retinitis pigmentosa

Proline links gut microbiome to depression

Novel variant in the DHX38 gene tied to congenital dyserythropoietic anemia with ring sideroblasts

Studies identify genetic risk factors for hyperemesis gravidarum and recurrence

AGEN-1571 reverses ILT-2-mediated immunosuppression to activate antitumor immunity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...